Stabilitech to have oral coronavirus vaccine ready for preclinical evaluation in 3 months

UK biopharma company Stabilitech is developing OraPro-COVID-19,  applying its OraPro technology with the aim of developing a viral vector with six weeks, and having a capsule ready for animal testing within 12 weeks.

The company said, “Because OraPro-COVID19 is thermally stable and in capsules, it can be self-administered orally by patients – this eliminates the queues of people waiting for injections, enabling the world’s most rapid deployment of vaccines. Stabilitech’s OraPro-COVID-19 vaccine development aims to deliver in 3 months an oral vaccine with two unique properties, capsule administration and broad mucosal and systemic immunity.”

More information on the company’s web page.